The post appeared first on Median Technologies ..read more

Imaging Biomarkers vs Imaging Endpoints In clinical trials using imaging, biomarkers and response criteria are used to assess the tumor evolution with therapy.  We have often heard these terms used interchangeably but the distinction between the two is important in a clinical trial with imaging.  Imaging biomarkers are often root contributors to a clinical trial’s endpoints, but they are not the same. What is a biomarker? A biomarker is a biological characteristic that is objectively measured and evaluated as an indicator of normal or pathological processes.   An ..read more

Business Intelligence (BI) is the combination of business analytics, data mining, data visualization, data tools and infrastructure, and best practices, which together can transform data into actionable insights that inform an organization’s business decisions . As an imaging CRO, Median uses Business Intelligence tools to streamline operations and provide a superior level of project management service. We use the power of BI to provide customized data visualization dashboards to support our main project activities and customer objectives. From overall project status to advanced monitoring of ..read more

The Value of Standardized Quality and Performance Metrics in Clinical Trials It’s not just tumor measurements that matter! Quality and Performance Measurements are critical too. Imaging biomarker metrics are not the only measurements that matter in oncology imaging trials. Quality and performance metrics are just as important and necessary for running a successful clinical trial with image analysis metrics as the endpoints. Biopharma organizations optimize clinical trials by operationalizing both quality and performance metrics.  The need for the industry to adopt vetted, standardized ope ..read more

Different Types of Imaging Criteria: Morphological Measures In oncology clinical trials, therapy is generally assessed using imaging response criteria involving imaging biomarkers. Imaging response criteria are used to define a “treatment response” status, used by the radiologist to evaluate whether the response to therapy is complete or partial or conversely, if the disease is not responding or even progressing. Imaging biomarkers are characteristics extracted from images under study and may vary with tumor or cancer types and with imaging modalities. They can be qualitative or quantitative ..read more

New White Paper – Innovations in Cancer Screening There has been great progress in the diagnosis and treatment of cancer in recent years, driven largely by the increased use of medical imaging technologies. As the world’s population ages, the number of new cases of cancer is set to rise — to 21.7 million new cases by 2030[i] —  which necessitates improved efficiencies in the use of imaging technologies. A new White Paper, Innovations in Cancer Screening showcases how innovations in imaging technology and the use of artificial intelligence and analytics are driving efficiencies in cancer imagin ..read more

Demystifying How Images Are Managed Between February 2017 and January 2018, ~41.4 million diagnostic imaging tests were performed in England[i]. That so many imaging tests were performed in a country with a population of ~55.3 million[ii] provides a small snapshot of the sheer volume of imaging data generated globally. As medical imaging has advanced in the digital age, so has managing and sharing the generated data. In this post, we provide a brief overview of commonly used systems and discuss how implementing proper processes and quality control can ensure maximum operational effectiveness a ..read more

ASCO 2018: Headlines and Highlights All eyes were on the American Society of Clinical Oncology (ASCO) Annual conference last week in Chicago watching for the latest clinical trial updates and translational innovations that will be tomorrow’s breakthrough cancer treatments and tests. Each year, the event attracts thousands working in the cancer field. And each year, the research presented at ASCO sets the tone for the cancer community in terms of what’s hot, and what’s not. If you didn’t attend the conference this year, you’ll want to know what you’ve missed. And if you did attend, covering the ..read more

Immunotherapy Update: Recent Advances in CAR T-cell Therapy As a measure of its promise, chimeric antigen receptor (CAR) T-cell therapy – where patients’ own immune cells are collected, genetically changed and used to treat their cancer – is the American Society of Clinical Oncology (ASCO) Advance of the Year for 2018.[i] This approach represents an exciting innovation that has the potential to transform cancer care.[ii] CAR T-cell therapy is clinically the most advanced of the adoptive cell transfer (ACT) class of immunotherapies, and has primarily been used in patients with advanced blood ca ..read more